Medicaid's prior authorization program and access to atypical antipsychotic medications

Health Affairs

Volumn 26, Issue 3, 2007, Pages 750-760

  Polinski, Jennifer M ^a,b   Wang, Philip S ^c   Fischer, Michael A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DRUG APPROVAL; ECONOMICS; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HUMAN; MEDICAID; METHODOLOGY; REIMBURSEMENT; RISK ASSESSMENT; STATISTICS; UNITED STATES;

ANTIPSYCHOTIC AGENTS; DRUG APPROVAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICAID; ORGANIZATIONAL CASE STUDIES; REIMBURSEMENT MECHANISMS; RISK ASSESSMENT; STATE GOVERNMENT; UNITED STATES;

EID: 34248586934     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.3.750     Document Type: Article

References (47)

1. J.S. Banthin and G.E. Miller, "Trends in Prescription Drug Expenditures by Medicaid Enrollees," Medical Care 44, no. 5 Supp. (2006): I27-I35.
2. P.J. Cunningham, "Medicaid Cost Containment and Access to Prescription Drugs," Health Affairs 24, no. 3 (2005): 780-789.
3. S.B. Soumerai et al., "A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline," Milbank Quarterly 71, no. 2 (1993): 217-252;
4. and National Pharmaceutical Council, "Pharmaceutical Benefits under State Medical Assistance Programs," 2004, http://www.npcnow.org/resources/ PharmBenefitsMedicaid.asp (accessed 25 April 2006).
5. M.B. Hamel and A.M. Epstein, "Prior-Authorization Programs for Controlling Drug Spending," New England Journal of Medicine 351, no. 21 (2004): 2156-2158;
6. and M.M. Mello, D.M. Studdert, and T.A. Brennan, "The Pharmaceutical Industry versus Medicaid - Limits on State Initiatives to Control Prescription-Drug Costs," New England Journal of Medicine 350, no. 6 (2004): 608-613.
7. M.A. Fischer et al., "Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors," New England Journal of Medicine 351, no. 21 (2004): 2187-2194;
8. M.A. Fischer et al., "Prior Authorization Policies for Selective Cyclooxygenase-2 Inhibitors in Medicaid: A Policy Review," Medical Care 44, no. 7 (2006): 658-663;
9. M.A. Fischer et al., "Responses to Risk of Suicidality in Children Treated with Antidepressants - A Review of Medicaid Policy," Psychiatric Services 58, no. 1 (2007): 135-138;
10. and M.A. Fischer et al., "Impact of Prior Authorization on Use of Angiotensin Receptor Blockers in U.S. Medicaid Programs," Pharmacoepidemiology and Drug Safety 15, no. 1 Supp. (2006): S45.
11. Banthin and Miller, "Trends in Prescription Drug Expenditures."
12. Ibid;
13. K.T. LaPensee, "Analysis of a Prescription Drug Prior Authorization Program in a Medicaid Health Maintenance Organization," Journal of Managed Care Pharmacy 9, no. 1 (2003): 36-44;
14. S.H. Zuvekas, "Prescription Drugs and the Changing Patterns of Treatment for Mental Disorders, 1996-2001," Health Affairs 24, no. 1 (2005): 195-205;
15. and M. Olfson et al., "National Trends in the Outpatient Treatment of Children and Adolescents with Antipsychotic Drugs," Archives of General Psychiatry 63, no. 6 (2006): 679-685.
16. J.A. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no. 12 (2005): 1209-1223.
17. S. Carson, M.S. McDonagh, and K. Peterson, "A Systematic Review of the Efficacy and Safety of Atypical Antipsychotics in Patients with Psychological and Behavioral Symptoms of Dementia," Journal of the American Geriatrics Society 54, no. 2 (2006): 354-361;
18. and R.S. Doody et al., "Practice Parameter: Management of Dementia (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology," Neurology 56, no. 9 (2001): 1154-1166.
19. C.C. Colenda et al., "Comparison of Adult and Geriatric Psychiatric Practice Patterns: Findings from the American Psychiatric Association's Practice Research Network," American Journal of Geriatric Psychiatry 10, no. 5 (2002): 609-617;
20. M.S. Giron et al., "Psychotropic Drug Use in Elderly People With and Without Dementia," International Journal of Geriatric Psychiatry 16, no. 9 (2001): 900-906;
21. I.R. Katz, B.W. Rovner, and L. Schneider, "Use of Psychoactive Drugs in Nursing Homes," New England Journal of Medicine 327, no. 19 (1992): 1392-1393;
22. and B.A. Briesacher et al., "The Quality of Antipsychotic Drug Prescribing in Nursing Homes," Archives of Internal of Medicine 165, no. 11 (2005): 1280-1285.
23. L.S. Schneider et al., "Effectiveness of Atypical Antipsychotic Drugs in Patientswith Alzheimer's Disease," New England Journal of Medicine 355, no. 15 (2006): 1525-1538.
24. Food and Drug Administration MedWatch, "2003 Safety Alert: RISPERDAL (risperidone)," 16 April 2003, http://www.fda.gov/medwatch/SAFETY/2003/ risperdal.htm (accessed 21 February 2007).
25. Health Canada, "Important Drug Safety Information: RISPERDAL (Risperidone) and Cerebrovascular Adverse Events in Placebo-Controlled Dementia Trials - Janssen-Ortho Inc.," 10 November 2002, http://www.hc-sc.gc.ca/dhp- mps/medeff/advisories-avis/prof/2002/risperdal_hpc-cps_e.html (accessed 7 June 2006);
26. and Health Canada, "Health Canada Endorsed Important Safety Information on ZYPREXA (olanzapine)," 10 March 2004, http://www.hc-sc.gc. ca/dhp-mps/medeff/advisories-avis/prof/2004/zyprexa_hpc-cps_e.html (accessed 7 June 2006).
27. FDA, "FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances," 11 April 2005, http://www.fda.gov/cder/drug/advisory/antipsychotics.htm (accessed 25 April 2006).
28. NPC, "Pharmaceutical Benefits."
29. Ibid.
30. Centers for Medicare and Medicaid Services, "State Drug Utilization Data," 2006, http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list.asp (accessed 3 August 2006).
31. Because the underlying Medicaid population could shift from quarter to quarter, we took a weighted average of the five quarters of data for each state, using as weights the total volume of drug use per quarter. This weighted measure gives a more appropriate measure of drug use and spending in each state.
32. Carson et al., "A Systematic Review";
33. and Doody et al., "Practice Parameter."
34. Soumerai et al., "A Critical Analysis."
35. B.S. Bloom and J. Jacobs, "Cost Effects of Restricting Cost-Effective Therapy," Medical Care 23, no. 7 (1985): 872-880.
36. T. Delate et al., "Clinical and Financial Outcomes Associated with a Proton Pump Inhibitor Prior-Authorization Program in a Medicaid Population," American Journal of Managed Care 11, no. 1 (2005): 29-36;
37. W.E. Smalley et al., "Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid Patients," New England Journal of Medicine 332, no. 24 (1995): 1612-1617;
38. and D.M. Hartung et al., "Effects of a Prior-Authorization Policy for Celecoxib on Medical Service and Prescription Drug Use in a Managed Care Medicaid Population,quot; Clinical Therapeutics 26, no. 9 (2004): 1518-1532.
39. Carson et al., "A Systematic Review."
40. Schneider et al., "Effectiveness of Atypical Antipsychotic Drugs."
41. P.S. Wang et al., "Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications," New England Journal of Medicine 353, no. 22 (2005): 2335-2341;
42. and FDA, "FDA Public Health Advisory."
43. Fischer et al., "Responses to Risk of Suicidality."
44. Agency for Healthcare Research and Quality, "DEcIDE Network," http://effectivehealthcare.ahrq.gov/decide/programBrief.cfm (accessed 28 June 2006).
45. Oregon Health and Science University, "Drug Effectiveness Review Project," http://www.ohsu.edu/drugeffectiveness/description/index.htm (accessed 28 June 2006).
46. W.H. Shrank et al., "The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions," Archives of Internal Medicine 166, no. 3 (2006): 332-337.
47. A. Baciu, K. Stratton, and S.P. Burke, eds., The Future of Drug Safety: Promoting and Protecting the Health of the Public (Washington: National Academies Press, 2006).